Less Is More, But Me-Too Should Not Be the Strategy for Lung Cancer Treatment in 2026

Area of Science:

• Oncology
• Pharmacology
• Health Economics

Background:

• Immune checkpoint inhibitors (ICIs) and targeted therapies (TTs) have revolutionized non-small cell lung cancer (NSCLC) treatment.
• Global access to these life-saving therapies is significantly limited by economic and regulatory disparities.

Purpose of the Study:

• To analyze the factors contributing to unequal worldwide access to advanced NSCLC therapies.
• To explore dose optimization as a strategy to enhance affordability and patient access.

Main Methods:

• Review of real-world data on ICI and TT accessibility.
• Analysis of cost, reimbursement, and regulatory landscapes.
• Evaluation of dose optimization strategies in NSCLC treatment.

Main Results:

• Cost barriers, fragmented reimbursement, and varied regulatory pathways create significant global inequities in NSCLC treatment access.
• Proliferation of similar drugs has not consistently lowered costs.
• Divergent regulatory decisions and trial designs further complicate drug availability.
• Dose optimization (reduced dosing, extended intervals) shows promise for maintaining efficacy while improving tolerability and reducing financial toxicity.

Conclusions:

• Addressing cost, reimbursement, and regulatory fragmentation is crucial for equitable NSCLC treatment access.
• Dose and schedule optimization present a rational approach to improve tolerability, reduce burden, and mitigate financial toxicity.
• Aligning regulatory frameworks with dose optimization can foster scalable, equitable, and sustainable NSCLC innovation.